Chapter 50: Cardiovascular Medications

The content systematically examines anticoagulants including heparin, warfarin, and enoxaparin, emphasizing laboratory monitoring parameters such as prothrombin time, international normalized ratio, and activated partial thromboplastin time, along with recognition of bleeding complications and administration of specific reversal agents. Thrombolytic agents like alteplase are reviewed with attention to appropriate timing, contraindications, and hemorrhage risks. The chapter covers antiplatelet drugs and their mechanisms for preventing thrombotic events while managing associated bleeding concerns. Cardiac glycosides, particularly digoxin, are examined for their positive inotropic effects, toxicity manifestations, therapeutic serum levels, and electrolyte interactions. Antihypertensive drug classes receive extensive attention, including diuretics categorized as thiazide, loop, and potassium-sparing variants with their distinct electrolyte effects; alpha-adrenergic blockers causing vasodilation and orthostatic responses; centrally acting sympatholytics with characteristic adverse effects; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with their respective side effect profiles; and additional agents like hydralazine and nitroprusside with specific monitoring requirements. Antianginal medications, particularly nitrates in sublingual and transdermal formulations, are reviewed with dosing protocols and safety considerations. Beta-blockers and calcium channel blockers are examined for their cardiovascular effects and potential adverse reactions. The chapter includes lipid-lowering agents such as statins, fibrates, and bile acid sequestrants with emphasis on monitoring and dietary considerations. Throughout, the focus remains on nursing implications, client education priorities, medication interactions, contraindications, and safe administration practices critical for cardiovascular nursing and examination success.